Melanoma & Skin Cancer

Tebentafusp use was associated with frequent dermatologic AEs, with desquamation and hypopigmentation observed in non-White patients in a real-world analysis.

Sensitivity analyses accounting for new primary melanoma did not diminish the RFS benefit favoring adjuvant pembrolizumab vs placebo in high-risk stage II melanoma.

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal postimmunotherapy toxicity management.

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Mario Sznol, MD, discusses adjuvant vs neoadjuvant immunotherapy in melanoma and highlights emerging vaccines, cell therapies, and T-cell engagers.

Data from the phase 2 SWOG S1512 trial showed a high pCR and durable survival outcomes with neoadjuvant pembrolizumab in resectable desmoplastic melanoma.

Mario Sznol, MD, discusses how the field is balancing dual checkpoint blockade and novel combinations in melanoma, plus unmet needs and emerging strategies.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

An sNDA has been filed with the FDA for aminolevulinic acid topical gel plus RhodoLED red light lamps in superficial basal cell carcinoma.

Real-world data show over an 40% response rate for lifileucel TIL therapy, for previously treated advanced melanoma.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Melphalan/HDS produced antitumor activity in metastatic uveal melanoma, including a consistent ORR across key subgroups.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of its efficacy data in melanoma.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving treatment landscapes in CSCC and melanoma.

PLN-101095 in combination with pembrolizumab led to responses in patients with ICI-refractory advanced solid tumors.

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.